39 related articles for article (PubMed ID: 8656260)
1. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
[TBL] [Abstract][Full Text] [Related]
2. Use of amifostine in the treatment of recurrent solid tumours in children.
Sidi V; Arsos G; Papakonstantinou E; Hatzipantelis E; Fragandrea I; Gombakis N; Koliouskas E
Hippokratia; 2007 Jan; 11(1):25-9. PubMed ID: 19582173
[TBL] [Abstract][Full Text] [Related]
3. The Neuroprotective Effect of Amitriptyline on Radiation-Induced Impairment of Hippocampal Neurogenesis.
Guo YR; Liu ZW; Peng S; Duan MY; Feng JW; Wang WF; Xu YH; Tang X; Zhang XZ; Ren BX; Tang FR
Dose Response; 2019; 17(4):1559325819895912. PubMed ID: 31903069
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
Kanat O; Evrensel T; Baran I; Coskun H; Zarifoglu M; Turan OF; Kurt E; Demiray M; Gonullu G; Manavoglu O
Med Oncol; 2003; 20(3):237-45. PubMed ID: 14514973
[TBL] [Abstract][Full Text] [Related]
5. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug-induced kidney disorders.
Kintzel PE
Drug Saf; 2001 Jan; 24(1):19-38. PubMed ID: 11219485
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
[TBL] [Abstract][Full Text] [Related]
8. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
9. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.
Hospers GA; Eisenhauer EA; de Vries EG
Br J Cancer; 1999 May; 80(5-6):629-38. PubMed ID: 10360638
[TBL] [Abstract][Full Text] [Related]
10. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
11. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
12. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
13. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
14. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
15. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
16. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
17. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]